Mac Etoch

I'd love to just get a sense of what you're seeing within life sciences. Onshoring, it's been talked about, but it's still on the come

There's been some concern around hospital utilization rates and procedure volumes. You posted some pretty strong growth in your healthcare consumables franchise.

can you just speak to what you saw in AST as the quarter progressed and particularly on the volume side?

Healthcare and Life Sciences, both had a pretty decent quarter from a capital equipment perspective. Backlog did decline sequentially

I'd just like to, you know, potentially get an update on your mitigation efforts

I'd just like to know how you would characterize the current conditions in that end market and how conversations with customers are evolving around US onshoring

I'd love to get your take on what's -- what you're seeing within the bioprocessing market

the Life Science segment saw a pretty strong increase in the segment's backlog sequentially

can you flesh out what you're seeing within the respective customer bases there

how are conversations progressing with clients? Has there been any change in behaviors

Could you just maybe break down how much of those -- how much of the growth that you're seeing is coming from maybe new program wins versus expansion of existing customers?

How are you thinking about valuations in the pipeline in front of you today? And are there any particular footholds you think an acquisition might slot you in

like to just get an update on how interest has trended for your organoid offerings in can you just give us a sense for how much revenue

I was just hoping to see if you all could flesh out some of the puts and takes around the cell and gene therapy end market just given the current challenges

Is there any way to frame up how much of your instrument revenue comes from the cell and gene therapy end market

How are you thinking about price today versus maybe at the start of the year and how that's reflected within guidance?

relatively flat year-over-year, excluding the incentive fee. And I think you highlighted some improving economics ahead of the automated line

if we were to look out over 2025 and then into 2026, I think you've added roughly 100 and you expected half of those to contribute to 2025

maybe can you just discuss what your how the year's progressing as compared to your internal expectations thus far